Immunic Inc (NAS:IMUX)
$ 1.27 -0.02 (-1.55%) Market Cap: 114.40 Mil Enterprise Value: 20.02 Mil PE Ratio: 0 PB Ratio: 1.37 GF Score: 41/100

Immunic Inc Discuss Overall MS Development Strategy - Corporate Call Transcript

Jul 01, 2021 / 12:00PM GMT
Release Date Price: $12.93 (+5.46%)
Operator

Good day, and welcome to the Immunic Therapeutics IMU-838 in Multiple Sclerosis Conference Call. (Operator Instructions) Please note this event is being recorded.

I'd now like to turn the conference over to Jessica Breu. Please go ahead.

Jessica Breu
Immunic, Inc. - Head of IR & Communications

Thank you, Jason. I also would like to welcome you to Immunic's conference call and webcast today to discuss our press release issued this morning to announce FDA clearance to begin with our Phase III ENSURE studies of IMU-838 in relapsing-remitting multiple sclerosis and our Phase II CALLIPER study of IMU-838 in progressive multiple sclerosis. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic.

Speaking on today's call are Dr. Daniel Vitt, our CEO and President; and Dr. Andreas Muehler, our Chief Medical Officer.

Before we begin, as always, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot